Charles Schwab
ATYR

Charles Schwab’s aTyr Pharma ATYR Stock Holding History

Charles Schwab’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-210,737
Closed -$164K – 3572
2026
Q1 		$164K Sell
210,737
-11,030
-5% -$9.31K ﹤0.01% 3323
2025
Q4 		$174K Sell
221,767
-39,276
-15% -$32.2K ﹤0.01% 3358
2025
Q3 		$188K Buy
261,043
+2,492
+1% +$11.3K ﹤0.01% 3355
2025
Q2 		$1.31M Buy
258,551
+218,640
+548% +$860K ﹤0.01% 2813
2025
Q1 		$121K Buy
39,911
+222
+0.6% +$809 ﹤0.01% 3314
2024
Q4 		$144K Buy
39,689
+13,000
+49% +$39.4K ﹤0.01% 3366
2024
Q3 		$47K Hold
26,689
– – ﹤0.01% 3418
2024
Q2 		$41.6K Hold
26,689
– – ﹤0.01% 3527
2024
Q1 		$52K Hold
26,689
– – ﹤0.01% 3366
2023
Q4 		$37.6K Hold
26,689
– – ﹤0.01% 3433
2023
Q3 		$42.2K Hold
26,689
– – ﹤0.01% 3419
2023
Q2 		$57.6K Hold
26,689
– – ﹤0.01% 3403
2023
Q1 		$56K Buy
26,689
+16,689
+167% +$36.6K ﹤0.01% 3333
2022
Q4 		$21.9K Hold
10,000
– – ﹤0.01% 3489
2022
Q3 		$30K Hold
10,000
– – ﹤0.01% 3436
2022
Q2 		$29K Hold
10,000
– – ﹤0.01% 3482
2022
Q1 		$54K Hold
10,000
– – ﹤0.01% 3520
2021
Q4 		$75K Buy
+10,000
New +$83.5K ﹤0.01% 3474
2016
Q2 		– Sell
-1,330
Closed -$74K – 3142
2016
Q1 		$74K Buy
1,330
+29
+2% +$2.2K ﹤0.01% 3012
2015
Q4 		$179K Buy
1,301
+38
+3% +$5.41K ﹤0.01% 2982
2015
Q3 		$182K Buy
+1,263
New +$288K ﹤0.01% 2973

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab's ATYR Position: Q2 2026 in Review

Charles Schwab sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 210,737 shares — an estimated $164K sold.

Charles Schwab first reported a position in ATYR in Q3 2015 and held it in 21 quarters. The position peaked at $1.31M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Charles Schwab reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • Charles Schwab sold 210,737 aTyr Pharma shares in Q2 2026, an estimated $164K.
  • Charles Schwab first reported a position in aTyr Pharma in Q3 2015 and held it in 21 quarters.
  • Charles Schwab's aTyr Pharma position peaked at $1.31M in Q2 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.